Sublingual Immunotherapy (SLIT) Works for House Dust-Mite Allergic Rhinitis in Children

Up to 40% of the world's population has been diagnosed with an allergic disease. The most prevalent allergy is to house dust mites (http://buff.ly/1jSF5Y6). House dust extract is used in conventional immunotherapy for house dust-mite (HDM) allergic rhinitis. This double blind, placebo-controlled trial evaluated the therapeutic efficacy and safety of sublingual immunotherapy (SLIT) with house dust extract in 31 pediatric patients with HDM allergic rhinitis.

Extract or placebo (1 ml) was administered at 10-fold dilution once weekly for 40 weeks.

The symptom scores in the active group began to decrease 24 weeks (6 months) after initiation of treatment and significant differences between the active and placebo groups were observed after 30 weeks.

The symptom scores for the last 4 weeks of the study were significantly lower than those for the first 4 weeks in the active group.

The only local adverse effect was a bitter taste reported by 1 patient. There were no other local or systemic adverse effects associated with SLIT.

SLIT with house dust extract for more than 30 weeks is safe and effective treatment for HDM allergic rhinitis in children.



Dust mite allergen avoidance. The main allergen is in the dust mite feces. Use 3 control measures for 3-6 months to see an effect on the allergy symptoms (click to enlarge the image).

References:

Sublingual Immunotherapy with House Dust Extract for House Dust-Mite Allergic Rhinitis in Children. Allergology International. 2010;59.

House dust mite sensitization in toddlers predicts wheeze at age 12 years (JACI, 2011).

Sublingual immunotherapy (SLIT) not effective in house dust mite-allergic children in primary care http://goo.gl/EdFHJ

Dust mite SLIT in children with allergic rhinitis and asthma: compliance 86%, symptoms improved in 65% of patients http://buff.ly/1lJEB5T